During the last session, Lineage Cell Therapeutics Inc (AMEX:LCTX)’s traded shares were 0.43 million, with the beta value of the company hitting 1.28. At the end of the trading day, the stock’s price was $0.82, reflecting an intraday loss of -1.86% or -$0.01. The 52-week high for the LCTX share is $1.61, that puts it down -96.34 from that peak though still a striking 6.1% gain since the share price plummeted to a 52-week low of $0.77. The company’s market capitalization is $154.05M, and the average intraday trading volume over the past 10 days was 0.44 million shares, and the average trade volume was 458.66K shares over the past three months.
Lineage Cell Therapeutics Inc (AMEX:LCTX) trade information
Lineage Cell Therapeutics Inc (LCTX) registered a -1.86% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.86% in intraday trading to $0.82, hitting a weekly high. The stock’s 5-day price performance is -3.00%, and it has moved by -9.24% in 30 days. Based on these gigs, the overall price performance for the year is -27.16%. The short interest in Lineage Cell Therapeutics Inc (AMEX:LCTX) is 15.77 million shares and it means that shorts have 35.94 day(s) to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Lineage Cell Therapeutics Inc (LCTX) estimates and forecasts
Statistics show that Lineage Cell Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Lineage Cell Therapeutics Inc (LCTX) shares have gone down -23.04% during the last six months, with a year-to-date growth rate less than the industry average at -25.00% against 17.10. In the rating firms’ projections, revenue will decrease -41.60% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.03M as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 1.32M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 1.25M and 2.09M respectively. In this case, analysts expect current quarter sales to shrink by -17.30% and then drop by -36.80% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 19.25%. While earnings are projected to return -23.61% in 2024.
LCTX Dividends
Lineage Cell Therapeutics Inc is due to release its next quarterly earnings on 2024-Nov-07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Lineage Cell Therapeutics Inc (AMEX:LCTX)’s Major holders
Lineage Cell Therapeutics Inc insiders own 0.44% of total outstanding shares while institutional holders control 50.35%, with the float percentage being 50.58%. BROADWOOD CAPITAL INC is the largest shareholder of the company, while 142.0 institutions own stock in it. As of 2024-06-30, the company held over 41.67 million shares (or 22.7798% of all shares), a total value of $41.55 million in shares.
The next largest institutional holding, with 9.56 million shares, is of BLACKROCK INC.’s that is approximately 5.2264% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $9.53 million.
